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ACQUIRED CARDIOVASCULAR DISEASETransapical aortic valve implantation after previous aortic valve
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270Objective: The ‘‘valve-in-valve’’ concept may be applied in patients with previously implanted biological aortic
valve prostheses. There are few reports of individual cases and as yet no clinical proof of safety and feasibility in
a larger group of patients. We report the single-center outcome of transapical implantation of aortic valves into
degenerated biological aortic valve prostheses (‘‘valve-in-valve’’) in very high-risk patients.
Methods: Since October 2008, 14 patients were treated by transapical valve implantation into degenerated bi-
ological aortic valve prostheses. Edwards SAPIEN (Edwards Lifesciences, Irvine, Calif) transcatheter heart
valves were used in all patients. Mean ( standard deviation) patient age was 73.3  13.1 years. Mean ( stan-
dard deviation) Society of Thoracic Surgeons score was 21.9%  10.9% (range, 4.2%–42.2%), and logistic
euroSCORE was 45.3%  22.2%. Preoperatively, all patients were in New York Heart Association functional
class III or IV.
Results: The procedural success was 100%. Preoperative transthoracic echocardiography mean transvalvular
gradient was reduced from 37.1  25.7 mm Hg to 13.1  6.4 mm Hg, and mean aortic valve area increased
from 0.68  0.23 cm2 to 1.35  0.48 cm2. There was no postoperative valve insufficiency. The postoperative
course was short and uneventful in all but 1 patient. One patient underwent reoperation 3 months later because
of endocarditis. Up to 20 months postoperatively, the patients were in New York Heart Association functional
class I or II.
Conclusions: Transapical aortic valve implantation after previous aortic valve replacement was feasible and
safe in our patients. The results are excellent with improvements in hemodynamics, but longer follow-up
with more patients is needed. (J Thorac Cardiovasc Surg 2011;142:270-7)Transcatheter aortic valve implantation is a successful new
procedure for high-risk patients with severe stenosis of the
native aortic valve. The procedure reduces surgical risk
and enables easier and faster postoperative recovery.1-10
Theoretically, the method may be useful in patients with
previously implanted biological aortic valve prostheses
(so-called valve-in-valve concept). This concept has been
experimentally proved byWalther and colleagues,11 and re-
cently introduced into clinical practice, but there is only lim-
ited experience worldwide.12-24 There are few anecdotal
reports and still no clinical proof of safety and feasibility
in a larger group of patients. The largest reports, published
recently, included only 4 cases from 2 institutions treated
by CoreValve (Medtronic Inc, Minneapolis, Minn)
implantation using transfemoral access in 3 patients and
transaxillary access in 1 patient,22 and a multicenter experi-e Deutsches Herzzentrum Berlin, Berlin, Germany.
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The Journal of Thoracic and Cardiovascular Surgence with transfemoral access in 2 patients and transapical
access in 8 patients.24 There are limited reports on Edwards
SAPIEN (Edwards Lifesciences, Irvine, Calif) valve im-
plantation and the transapical approach. We present our ex-
perience in 14 consecutive patients who were treated by
transapical implantation of Edwards SAPIEN valves into
failed aortic bioprostheses and were followed up 5 to 20
months postoperatively.MATERIALS AND METHODS
Since October 2008, a minimally invasive transcatheter redo aortic
valve procedure was performed in 14 patients with degenerated biological
aortic valve prostheses (Table 1). The transapical means of implantation us-
ing the Edwards SAPIEN transcatheter heart valves was used in all cases.
All patients had a very high risk for conventional redo surgery because of
comorbidities (as represented by the risk scores) or technical surgical con-
siderations (porcelain aorta in 4 patients) (Tables 1 and 2). All patients
underwent operation on an elective basis and were preconditioned for the
procedure to optimize the organ functions (eg, renal function). The
primary valve surgery was performed at a mean of 8.9  4.7 years
before the transapical procedure (Table 3). We accepted patients with de-
generated biological valves with an external diameter of 23 mm or more.
Patients with a smaller prosthesis (eg, external diameter 21 mm) had an in-
ternal diameter of approximately 17 mm and were accepted for the proce-
dure only as an ultima ratio procedure. Paravalvular leakage and acute/
subacute endocarditis were absolute contraindications for the procedure.
Eleven patients had degeneration of a biological xenograft prosthesis (1 pa-
tient with a previously implanted Edwards SAPIEN valve), and 3 patientsery c August 2011
Abbreviations and Acronyms
LVEF ¼ left ventricular ejection fraction
SD ¼ standard deviation
TEE ¼ transesophageal echocardiography
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diameter of the degenerated prosthesis (as given by the manufacturer)
was 21 mm in 4 patients, 23 mm in 7 patients, and 25 to 28 mm in 3
patients (Tables 3 and 4). We did not turn down any patients (eg, with
larger valves or because of a particular type of valve). The size of the
used valve prosthesis depends on the internal diameter of the old
prosthetic valve. This criterion is similar as for the choice of the valve
size for a stenotic native valve (see below).10 We implanted four 26-mm
valves (in homografts and previously implanted Edwards SAPIEN valve)
and ten 23-mm valves (in other degenerated valves) in patients. The study
was approved by the institutional review committee of the Deutsches Herz-
zentrum Berlin. All patients gave written informed consent.
Implantation Technique
Aortic valve implantation was performed through a mini left anterior
thoracotomy via the transapical route with a balloon-expandable transcath-TABLE 1. Patients’ preoperative characteristics
Parameter Value (± SD) Range
No. of patients, n 14 –
Female, n 5 –
Age, y 73.3  13.1 38–87
BMI, kg/m2 26.8  4.0 20.3–35.7
Logistic euroSCORE,% 45.3  22.2 21.1–89.0
STS score,% 21.9  10.9 4.2–42.2
Aortic valve area, cm2 0.68  0.23 0.48–1.19
dP max, mm Hg (TTE) 57.7  36.0 15–140
dP mean, mm Hg (TTE) 37.1  25.7 8–100
LVEF,% 45  13 10–65
LVEDD, mm 55  11 42–80
Malignancy, n 2 –
Pulmonary hypertension, n 8 –
COPD, n 6 –
Peripheral art. disease, n 8 –
CAD, n 12 –
Previous stroke, n 6 –
Previous CABG, n 8 –
Previous PM/ICD, n 2 –
Previous MVR, n 1 –
Porcelain aorta, n 4 –
Severe AI, n 4 –
Severe MI, n 4 –
Creatinine, mg/dL 1.3  0.4 0.7–2.0
NT-proBNP, pg/mL 5517  9806 68–32,879
SD, Standard deviation; BMI, body mass index; STS, Society of Thoracic Surgeons;
dP, transvalvular gradient; TTE, transthoracic echocardiography; LVEF, left ventric-
ular ejection fraction; LVEDD, left ventricular end-diastolic diameter; NYHA, New
York Heart Association; COPD, chronic obstructive pulmonary disease; CAD, coro-
nary artery disease; CABG, coronary artery bypass grafting; PM, pacemaker; ICD,
implantable cardioverter-defibrillator; MVR, mitral valve replacement; AI, aortic in-
sufficiency; MI, mitral insufficiency; NT-proBNP, B-type natriuretic peptide.
The Journal of Thoracic and Caeter stent-prosthetic xenograft (Edwards SAPIEN transcatheter heart
valves) 23 or 26 mm in diameter. Implantations were performed in our hy-
brid operation room with a monoplane angiography system by our team of
cardiac surgeons, a cardiologist, and anesthesiologists. A perfusionist and
a heart–lung machine were present in the operating room. The principal
surgical technique was described in detail by Walther and colleagues,3
and we made some modifications.10,25 First, balloon dilatation of the
degenerated bioprosthesis was not principally performed. The most
important modification of the technique was slow and gradual valve
deployment (and not at once by forced and rapid inflation of the balloon,
as in the original technique) supported by simultaneous angiographic
visualization10,25 (Figures 1 and 2). The old stented prosthesis was an
excellent guide for the positioning of the new valve during valve
deployment (Figure 1). If the position of the new prosthesis was not ideal,
slow and gradual balloon inflation enabled easy correction of the valve po-
sition by pushing or pulling the catheter with the stented prosthetic valve.
The valve-in-valve concept applied to a degenerated homograft in the aor-
tic position or stentless xenograft aortic valve prosthesis is technically al-
most identical to the transapical aortic valve implantation into a stenotic
native aortic valve. Especially in these situations, simultaneous angio-
graphic visualization of the aortic root during slow valve deployment en-
ables optimal positioning of the valve with perfect presentation of the
relationships among the prosthetic valve, aortic valve annulus, aortic cusps,
and coronary arteries.10,25 The definitive optimal positioning of the new
valve depends on the type of the old valves: For stentless valves, the rule
of valve positioning is as for native valves,3 and the position of a new valve
in a degenerated stented valve is to be a bit higher to achieve good anchor-
age of the new valve into the old valve and to move and displace the degen-
erated leaflets of the previously implanted valve toward the scaffold of the
old valve (Figures 1 and 2). The valve was always implanted during a short
phase of ventricular rapid pacing of the heart.3,25 Balloon-expandable
transcatheter stent-prosthetic xenograft valves of 23 or 26 mm diameter
with the corresponding delivering system (both Edwards Lifesciences)
were used in all patients. The size of the new valve used was determined
according to the internal diameter of the old prosthetic valve. Both internal
and external diameters were measured by preoperative chest computed to-
mography, transthoracic echocardiography, and intraoperative transeso-
phageal echocardiography (TEE), and data were analyzed and compared
with the data of the manufacturers. A valve size of 23 mm was used for
an internal diameter of the first prosthesis less than 21 mm, and a 26-mm
prosthesis was used for an internal diameter more than 21 mm. The proce-
dure was monitored by fluoroscopy, angiography, and intraoperative TEE.
The hemodynamic parameters (gradient, aortic valve area) were intraoper-
atively taken only by TEE. The antegrade systolic velocity across the nar-
rowed aortic valve, or aortic jet velocity, is measured using continuous-
wave Doppler ultrasound. Transaortic pressure gradient (P) is calculated
from velocity (v) using the Bernoulli equation as: dP¼ 4v2. The maximum
gradient is calculated from maximum velocity: dPmax ¼ 4vmax2, and the
mean gradient is calculated by averaging the instantaneous gradients over
the ejection period. Aortic valve area is calculated on the basis of the
continuity-equation concept that the stroke volume (SV) ejected through
the LV outflow tract (LVOT) all passes through the stenotic orifice
(AVA), and thus SV is equal at both sites: SVAV ¼ SVLVOT . Because vol-
ume flow rate through any CSA is equal to the CSA times flow velocity
over the ejection period (the VTI of the systolic velocity curve), this equa-
tion can be rewritten as AVA 3 VTIAV ¼ CSALVOT 3 VTILVOT .
Invasive measurements were not performed to keep the procedure as
simple as possible. If any problems had been anticipated, invasive monitor-
ing would have been used. The temporary epicardial pacemaker wires were
left in place for 1 week.Postoperative Medication
Postoperative medication consisted of aspirin and clopidogrel in addi-
tion to patients’ individual therapy for other causes.rdiovascular Surgery c Volume 142, Number 2 271
TABLE 2. Patients’ baseline characteristics
Patients Age (y) Gender (female) euroSCORE (%) STS score (%) NYHA class Most relevant risk factor
Patient 1 38 – 23.0 13.1 IV Porcelain aorta
Patient 2 74 – 27.8 18.9 III Diffuse CAD
Patient 3 75 – 89.0 42.2 III Poor LVEF
Patient 4 70 – 22.4 17.3 III Poor LVEF
Patient 5 79 þ 59.8 28.7 IV Poor LVEF
Patient 6 86 þ 61.5 21.6 IV Age (polymorbidity)
Patient 7 81 – 55.9 27.7 IV Age (polymorbidity)
Patient 8 84 – 66.5 37.0 III Porcelain aorta
Patient 9 85 þ 77.2 33.0 IV Lung function
Patient 10 51 þ 21.8 13.1 III Porcelain aorta
Patient 11 84 þ 48.5 29.4 III Lung function
Patient 12 75 – 27.8 9.4 III Diffuse CAD
Patient 13 73 – 21.1 11.3 III Polymorbidity
Patient 14 71 – 31.8 4.2 IV Porcelain aorta
STS, Society of Thoracic Surgeons; NYHA, New York Heart Association; CAD, coronary artery disease; LVEF, left ventricular ejection fraction.
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Procedural Course
Technical procedural success was achieved in all patients.
There was no conversion to open surgery. Cardiopulmonary
bypass was used electively in 1 patient with a left ventricular
ejection fraction (LVEF) of 10%. The cardiopulmonary
bypass time was 12 minutes. One patient also received
planned and elective coronary artery stenting for coronary
artery disease. A renal artery stent was implanted electively
in 1 patient. All procedures were straightforward with no
complications. The diameters of the new implanted valves
were 23 mm in 10 patients and 26 mm in 4 patients. The
mean duration of the whole surgical procedure was 69 min-
utes (range, 45–120 minutes). The mean amount of contrast
medium used per procedurewas 76mL (range, 36–137mL).
Mean fluoroscopy time was 9.8 minutes (range, 3.7–25.6
minutes).TABLE 3. Data of previous aortic valve replacement and new implanted E
Patients Time (y) Prosthesis (type)
Patient 1 12.0 Homograft
Patient 2 8.6 Hancock (Medtronic Inc, Minneapolis, Minn)
Patient 3 12.7 Homograft
Patient 4 3.6 Hancock (Medtronic Inc)
Patient 5 0.9 SAPIEN (Edwards SAPIEN,
Edwards Lifesciences, Irvine, Calif)
Patient 6 13.9 Freestyle (Medtronic Inc)
Patient 7* 6.9 Carpentier-Edwards
Patient 8* 9.3 Mosaic (Medtronic Inc)
Patient 9 14.0 Hancock (Medtronic Inc)
Patient 10 13.4 Carpentier-Edwards (after previous homograft)
Patient 11 2.7 Hancock ultra (Medtronic Inc)
Patient 12 2.1 Hancock ultra
Patient 13 9.8 Carpentier-Edwards
Patient 14 14.3 Homograft
TAVI , Transapical aortic valve implantation. *Patient died during follow-up.
272 The Journal of Thoracic and Cardiovascular SurgProcedural Echocardiographic Data
After implantation of a new valve, the mean ( standard
deviation [SD]) intraprocedurally measured TEE transvalv-
ular gradient decreased from 27.2  16.9 mm Hg to 10.3 
5.0 mm Hg (range, 3.0–25 mm Hg) (Table 5). The mean (
SD) aortic valve area increased from 0.81  0.36 cm2 to
1.35  0.48 cm2 (range, 0.85–2.50 cm2) (Table 5). There
was no valve insufficiency. For the 10 stented valves, the
mean ( SD) transvalvular gradient decreased from 22.9
 12.9 mmHg to 10.9 4.7 mmHg. The mean ( SD) aor-
tic valve area increased from 0.70  0.25 cm2 to 1.29 
0.46 cm2. For the 4 stentless valves, the mean ( SD) trans-
valvular gradient decreased from 38.5  20.8 mm Hg to
9.5  4.9 mm Hg. The mean ( SD) aortic valve area in-
creased from 0.82  0.28 cm2 to 1.49 0.51 cm2. The pre-
operative mean ( SD) LVEF was 45%  13% with
a range from 10% to 65%. At the end of the procedure,dwards SAPIEN transcatheter heart valves
Size of old
valve (mm) Stentless
Size of new
TAVI valve (Edwards
SAPIEN) (mm)
Follow
up (mo)
23 þ 26 20
23 – 23 19
28 þ 26 19
23 – 23 18
26 – 26 17
23 þ 23 17
21 – 23 3*
23 – 23 5*
21 – 23 13
21 – 23 13
21 – 23 11
23 – 23 10
23 – 23 3
25 þ 26 2
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TABLE 4. Preoperative transthoracic echocardiographic data of degenerated valves
Patients Prosthesis (type)
Size of the old
valve (mm)
dP max
(mm Hg)
dP mean
(mm Hg)
Valve
regurgitation ()
Patient 1 Homograft 23 96 65 2
Patient 2 Hancock (Medtronic Inc) 23 140 100 2
Patient 3 Homograft 28 20 10 2
Patient 4 Hancock (Medtronic Inc) 23 30 20 3
Patient 5 SAPIEN (Edwards SAPIEN) 26 17 8 3
Patient 6 Freestyle (Medtronic Inc) 23 80 50 1
Patient 7 Carpentier-Edwards 21 15 8 3
Patient 8 Mosaic (Medtronic Inc) 23 40 25 1
Patient 9 Hancock (Medtronic Inc) 21 43 25 2–3
Patient 10 Carpentier-Edwards 21 48 32 1
Patient 11 Hancock ultra (Medtronic Inc) 21 88 51 0
Patient 12 Hancock ultra 23 54 36 0–1
Patient 13 Carpentier-Edwards 23 89 70 1
Patient 14 Homograft 25 48 20 3
dP, Transvalvular gradient.
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difference was not statistically significant (P ¼ .59).Postoperative Clinical Outcome
The early postoperative course was uneventful in all but 1
patient who had respiratory problems. There were no post-
operative bleeding complications, no wound healing prob-
lems, no postoperative myocardial infarction, no need for
temporary postoperative dialysis, no need for postoperative
pacemaker implantation, and no new clinical neurologic
deficits. Two patients died of pulmonary problems and com-
plications of urologic surgery 3 and 4.5 months after valve
implantation, respectively. At the end of the follow-up, all
other patients were in New York Heart Association class IFIGURE 1. A, The metallic ring of the degenerated aortic valve prosthesis (ar
position of the new valve is obtained by precise correction of the position relati
inflated, and the valve deployment begins. D, Forced complete inflation of the b
comitant angiography is performed. The optimal positioning of the new valve i
tween 2/3 :
1/3 and
3/4 :
1/4 . This higher position when the implantation is performed
implanted valve and should compress the old prosthetic leaflets toward the scaffo
prosthesis.
The Journal of Thoracic and Caor II. One patient underwent reoperation 3 months after
the procedure because of endocarditis. He received a new
biological valve by the conventional procedure, and his fur-
ther postoperative course was uneventful. The explanted
valves showed excellent fit of the transapically implanted
valve in the original biological valve.Follow-up Echocardiographic Data
At the end of the follow-up, transthoracic echocardio-
graphic examinations showed a mean ( SD) transvalvular
gradient of 13.1  6.4 mm Hg (range, 5.0–29 mm Hg).
There was no valve insufficiency. The mean ( SD) LVEF
was 52%  11% (range, 30%–70%), and the mean left
ventricular end-diastolic diameter was 53  10 mm (range,row) enables an optimal working position to be easily found. B, The ideal
ng to the metallic ring of the old prosthesis. C, The balloon is only slightly
alloon is performed, and the valve is deployed in the desired position. Con-
n the old stented degenerated valve in regard to its annulus seems to be be-
in a stented valvemay enable better anchoring in the ring of the previously
ld of the old valve, not allowing overhanging of the old leaflets over the new
rdiovascular Surgery c Volume 142, Number 2 273
FIGURE 2. Angiography shows correct positioning of the new valve inside
the old prosthesis with no paravalvular leak or valvular insufficiency. Note
hour-glass shape of the new prosthesis enabling firm anchorage of the new
prosthesis inside the old one. However, if the new valve is positioned too
high, the wider dilation of the distal (aortic) end of the new valve in compar-
isonwith its proximal (ventricular) endmay cause transvalvular insufficiency.
TABLE 5. Intraoperative transesophageal echocardiographic parameters o
heart valves after valve-in-valve procedure
Before implantatio
Patients Prosthesis (type)
Size
(mm)
Annulus
(mm)
dP max
(mm Hg)
Patient 1 Homograft 23 19.5 94
Patient 2 Hancock (Medtronic Inc) 23 18.3 33
Patient 3 Homograft 28 20.8 11
Patient 4 Hancock (Medtronic Inc) 23 13.1 24
Patient 5 SAPIEN (Edwards SAPIEN) 26 19.0 17
Patient 6 Freestyle (Medtronic Inc) 23 16.9 76
Patient 7 Carpentier-Edwards 21 18.8 38
Patient 8 Mosaic (Medtronic Inc) 23 17.6 52
Patient 9 Hancock (Medtronic Inc) 21 14.6 43
Patient 10 Carpentier-Edwards 21 14.5 12
Patient 11 Hancock ultra (Medtronic Inc) 21 14.9 89
Patient 12 Hancock ultra 23 18.9 22
Patient 13 Carpentier-Edwards 23 17.5 73
Patient 14 Homograft 25 20.7 68
Mean  SD 17.5  2.3 46.5  27.8 2
Range 13.1–20.8 11–94
dP, Transvalvular gradient; AVA, aortic valve area; SD, standard deviation.
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regressed in all patients and was not higher than grade 2 at
the follow-up.
DISCUSSION
Favorable Outcome and Fast Postoperative Recovery
Our experience with 14 patients shows that transapical
redo aortic valve implantation (‘‘valve-in-valve’’ concept)
is a technically feasible, simple, and safe procedure after
previous aortic valve replacement. The early results were
excellent with an immediate improvement in hemodynam-
ics. The patients’ postprocedural recovery was impressively
fast with a prompt and significant alleviation of symptoms
that remained stable throughout the follow-up. We have
not observed any valvular insufficiency. We used the trans-
apical approach for implantation of Edwards SAPIEN
transcatheter heart valves in all cases. It might be expected
that the results of all types of transcatheter aortic valve im-
plantation (transfemoral, transaxillary) with other types of
valve would yield comparable results. Although our team
uses all approaches of transcatheter aortic valve implanta-
tion (transfemoral, transapical, or transaxillary) with an ex-
perience of more than 300 transcatheter aortic valve
implantations in a 2-year period, we decided to perform
all valve-in-valve procedures by transapical implantation,
which is a simple and direct procedure. The method pos-
sesses several advantages over the transfemoral (or transax-
illary) route. The transapical approach is independent of the
degree of the patient’s peripheral arterial disease. Further-
more, advancing the wire antegradely through the valve is
easy, rapid, and simple, in comparison with the retrogradef old degenerated prostheses and new Edwards SAPIEN transcatheter
n (old prosthesis) After implantation (new prosthesis)
dP mean
(mm Hg)
AVA
(cm2)
Annulus
(mm)
dP max
(mm Hg)
dP mean
(mm Hg)
AVA
(cm2)
64 0.50 17.3 29 16 0.85
21 1.02 15.8 20 11 1.20
6 1.19 18.5 7 3 2.03
16 0.48 12.1 13 8 2.50
8 1.66 18.9 17 10 1.20
42 0.60 15.6 14 7 1.14
24 0.70 18.3 7 4 1.50
29 0.57 15.9 39 23 0.89
25 0.70 13.3 21 13 0.90
7 1.30 13.9 18 12 1.10
45 0.55 14.2 18 10 1.30
11 0.65 15.5 17 9 0.85
43 0.40 15.0 20 9 1.50
42 1.00 19.9 23 12 1.95
7.2  16.9 0.81  0.36 16.0  2.2 18.6  8.0 10.3  5.0 1.35  0.48
6–64 0.40–1.66 12.1–19.9 7–39 3–23 0.85–2.50
ery c August 2011
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duce or eliminate cerebral embolization during this phase of
the procedure. We also expect a lower rate of neurologic
complications because the danger of embolization during
manipulation in the aortic arch is reduced or eliminated
by the transapical route. However, our main reason for the
exclusive use of the transapical approach is the excellent
and safe possibility of precise deployment of the new valve
in the desired position by applying our modified valve
implantation technique (‘‘Berlin addition’’).10,25 The
inflation of the balloon during valve deployment is
performed slowly, and not instantly as described in the
principal technique,3 allowing the valve position to be cor-
rected if necessary. We would choose the transfemoral ap-
proach only when it is necessary to avoid general
anesthesia and would perform the procedure with local
anesthesia.
Decision-Making Process
It is not well established which patients are suitable for
such an intervention, which steps during the screening
phase are important, which examinations are mandatory,
and which previous bioprostheses are technically suitable
for the procedure. According to our limited preliminary ex-
perience, we consider all types of biological prostheses to
be principally suitable for valve-in-valve implantation, but
not all sizes of prosthesis (see below). A stented valve is op-
timal for implantation because there is no risk of postoper-
ative atrioventricular block, coronary obstruction, or
paravalvular leak. In contrast, stentless valves and allografts
(homografts) are suitable for implantation, but in this situa-
tion the rules are the same as for transapical aortic valve im-
plantation in the native aortic valve (risk of coronary
obstruction, paravalvular leak, or atrioventricular block
postoperatively). Our patients were younger than our usual
high-risk population for transcatheter aortic valve implanta-
tion,10 but they were also more morbid. The average age
was only 73.3 years, with an average Society of Thoracic
Surgeons score of 21.9% and logistic euroSCORE of
45.3%. Four patients had severe functional mitral valve re-
gurgitation. This polymorbidity and high predicted risk for
conventional heart surgery were the main reasons for apply-
ing this new approach.
Important Preoperative Steps During the Screening
Phase
Preoperatively it is mandatory to exclude acute or sub-
acute endocarditis. Patients’ history should be meticulously
evaluated in regard to fever and infections during the last
several months, especially in the case of prosthetic failure
shortly after primary valve replacement (eg, 2–3 years).
Early valve degeneration, which is rare, should be distin-
guished from endocarditis and valve thrombosis, because
these can cause embolic or infectious complications. Preop-The Journal of Thoracic and Caerative transthoracic echocardiography and TEE determine
the degree of stenosis, valve gradients and aortic valve area,
aortic regurgitation, and internal diameter of the old valve.
These examinations should identify the cause of valve de-
generation, amount of calcification, and possible floating
structures on the leaflets to prevent possible postoperative
embolic events. Most important, the examinations should
exclude paravalvular leak as a cause of aortic regurgitation,
in which case the ‘‘valve-in-valve’’ concept is contraindi-
cated. Coronary angiography is necessary to exclude or
identify concomitant coronary artery disease. In patients
with stentless prostheses, the distances from the annulus
to the coronary ostia should be determined by cardio com-
puted tomography.
‘‘Valve-in-Valve’’ Concept as a Palliative Approach
The diameter of the previously implanted biological aor-
tic valve prosthesis is the main limiting factor for the
‘‘valve-in-valve’’ concept. A stented bioprosthesis with an
external diameter of 21 mm usually has an internal diameter
of approximately 17 mm. The new prosthesis in the old
prosthesis would have a reduced valve orifice area com-
pared with after primary transapical aortic valve implanta-
tion. Our data of primary transapical aortic valve
implantation have been published.10 The mean postopera-
tive transvalvular gradient was 6.28  2.94 mm Hg (range,
1.19–15.56 mm Hg), and the mean aortic valve area was
1.88  0.51 cm2 (range, 0.85–3.37 cm2). Our echocardio-
graphic data after valve-in-valve implantation still represent
aortic valve stenosis but less than before transapical aortic
valve implantation. This ‘‘palliative approach’’ may be
enough for elderly or very high-risk patients requiring con-
ventional redo valvular surgery. Most of these patients have
reduced mobility and less demand for physical activities.
Most of them should have an improvement in their quality
of life, with relief of symptoms (dyspnea or angina) after re-
duction of the valve stenosis by transcatheter redo aortic
valve implantation. This issue of prosthesis mismatch is
a key problem in applying this strategy in all high-risk pa-
tients with failed aortic bioprosthesis. We believe that the
implantation is still possible and acceptable (as in our 3 pa-
tients with previously implanted 21-mm stented valves) if
the internal diameter of the first valve is approximately
17 to 18 mm (corresponding to a 21-mm stented valve),
but it should be considered only as a palliative procedure.
Therefore, this can be performed only in very high-risk pa-
tients and elderly patients in New York Heart Association
class III or IV.
Advantages of the Procedure Over Conventional
Aortic Valve Replacement
The procedure excludes the need for extensive surgical
preparation because of the significant adhesions and, there-
fore, eliminates possible bleeding complications. Also,rdiovascular Surgery c Volume 142, Number 2 275
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coronary artery bypass surgery. The procedure can be per-
formed on the beating heart without aortic cross-clamping
or cardiopulmonary bypass, reducing postoperative neuro-
logic complications. The method is of extraordinary impor-
tance for patients with poor left ventricular function. There
is no ischemic cardioplegic arrest, and myocardial recovery
can already be seen in the operating room after elimination
of the aortic valve stenosis. Cardiopulmonary bypass also
can be used in patients with cardiogenic shock or poor
left ventricular function to improve the safety of the proce-
dure.10 If used, the cardiopulmonary bypass time is then
very short. In patients with significant coronary artery dis-
ease, a coronary stent can be simultaneously placed on an
elective basis, if necessary.10
We consider the valve-in valve concept only as an alter-
native to standard surgery. With the exception of patients
with porcelain aorta, all patients could have undergone op-
eration via the conventional technique at Deutsches Herz-
zentrum Berlin. We perform more than 800 conventional
aortic valve procedures at Deutsches Herzzentrum Berlin
every year, and as a ‘‘high-volume institution,’’ the experi-
ence with conventional surgery in octogenarians and even
nonagenarians has been expanded with favorable results.
In most cases it is possible to perform conventional aortic
valve surgery with an acceptable success rate, but the ad-
vantage of transcatheter aortic valve implantation over con-
ventional surgery is faster and shorter postoperative
recovery and fewer postoperative complications. Complica-
tions in these older patients are typically followed by a se-
quence of several others.
Advantages of the Procedure Over ‘‘Conventional’’
Transapical Aortic Valve Implantation
Principally, the intraoperative procedural course is sim-
pler than the standard transapical valve implantation into
a stenotic native aortic valve. (1) There is no need for bal-
loon dilatation of the degenerated biological valve. Per-
forming balloon valvuloplasty in a patient with failed
aortic valve prosthesis is debatable, because it carries
a risk of embolization and possible immediate massive aor-
tic valve regurgitation that has to be treated by prompt im-
plantation of a new valve. (2) Valve deployment is simple
with the degenerated stented prosthesis as an excellent
guide for the positioning of the new valve. Furthermore,
our modification25 with slow and gradual inflation of the
balloon with a mounted new valve enables precise posi-
tioning of the valve. Some further minimal corrections in
valve positioning are possible before it achieves its final
open state. In this manner the procedure is completely un-
der control and under visualization. Despite this modifica-
tion, the valve deployment remains a short procedure,
lasting only 5 to 10 seconds. Valve-in-valve treatment of
a stentless bioprosthesis is a somewhat challenging proce-276 The Journal of Thoracic and Cardiovascular Surgdure because of the lack of landing support (stent) for the
anchoring of the transcatheter valve. The valve should be
positioned at the level of the bioprosthetic valve. The ab-
sence of radiopaque markers (no valve calcification and
no radiopaque markers in stentless valves) makes the posi-
tioning of the transcatheter valve comparable to the im-
plantation of a transcatheter valve into a native stenotic
aortic valve or somewhat more difficult. However, simulta-
neous angiography during slow and gradual valve deploy-
ment enables excellent visualization of the aortic root and
the relationships among the prosthetic valve, aortic valve
annulus, aortic cusps, and coronary arteries, and fine posi-
tioning of the new valve.25 (3) The risk of coronary artery
obstruction is decreased or even eliminated in patients with
previously implanted stented bioprostheses (but not in
stentless ones). (4) The need for procedurally caused pace-
maker implantation is completely eliminated in patients
with previously implanted stented valves because there is
no risk of heart block as the new valve does not put pres-
sure on the septum. None of our patients required postop-
erative pacemaker implantation. However, for safety
reasons and per our standard institutional policy, we left
epicardial wires in place for 1 week. (5) The amount of
contrast medium used during the procedure is less than
for ‘‘conventional’’ transapical valve implantation.
Theoretically, transcatheter valve implantation in the na-
tive calcified aortic valve may have the advantage that liv-
ing tissue will have the potential for ingrowth into the
new prosthesis, which would secure it over time. However,
in a valve-in-valve procedure this ingrowth might not occur
and there could be a theoretic risk when the expansion force
of the prosthetic material decreases after longer follow-up,
which might cause loosening of the prosthesis.
Durability of a New Valve
The long-term results are unknown. However, if the valve
should degenerate earlier than expected, the risk of a new
redo operation with conventional aortic valve replacement
is not increased or is even reduced. Transcatheter valve im-
plantation might be a good temporary solution. If a patient
is not in stable condition, the ‘‘valve-in-valve’’ concept may
be applied to improve clinical status before redo conven-
tional heart surgery. If the good short-term results should
be proven during a longer follow-up in a larger patient col-
lective, transcatheter redo valve procedure would be a real
alternative for standard redo valve replacement in all pa-
tients with degenerated biological valves. Theoretically, in
regard to the type of the degenerated biological valve, pri-
mary pericardial bioprosthesis may have different results
from the porcine bioprosthesis because of a risk of coronary
ostia occlusion in a pericardial bioprosthesis.
The indications for the size choice for the new valve are
similar as for primary valve implantation.3,10,25 We need at
least 2-mm oversizing for the new valve. In a borderlineery c August 2011
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Dsituation with an internal diameter of 21 mm for an old
prosthesis, we would use a 23-mm prosthesis. In this
particular situation, the size is chosen on an individual
basis because the anchorage of the prosthesis should be
good. We do not yet know the long-term durability of the
valve-in-valve procedure; therefore, the question is: When
a 26-mm prosthesis is put into a degenerated bioprosthesis
with an internal diameter of 21 mm, would this new valve
open and close fully without any folds that may have an im-
pact on long-term durability? It is an additional reason for
more experience with more patients and longer follow-up.
Study Limitations
There are 3 main study limitations. (1) We had no control
group of patients undergoing conventional aortic valve re-
placement, (2) the number of patients was small, and (3)
the follow-up was limited. We claim that transapical aortic
valve implantation after previous aortic valve replacement
significantly reduces the risk of conventional re-do aortic
valve surgery, but there is no comparison between the avail-
able 2 techniques. However, the calculated operative risk
for the conventional operation as assessed by the Society
of Thoracic Surgeons and euroSCORE is a valuable method
of evaluating the procedural success. Our conclusions are
based on our experience in only 14 patients. However,
this is the largest single-center experience worldwide to
date. We consider that our data show only a trend, and
a study with larger patient numbers is required.
CONCLUSIONS
The valve-in-valve concept offers a new strategy for the
treatment of patients with failed bioprostheses. The concept
may have important advantages over conventional redo aor-
tic valve replacement because of very low operative risk in
comparison with the conventional redo procedure. This
method is new and experience with it is, as yet, little. The
early results were excellent, but a longer follow-up is
needed. This new procedure needs to be validated by ran-
domized trials and long-term follow-up results. Therefore,
the indication for this type of surgery should be restrictively
applied for high-risk patients until additional proof is avail-
able. For the time being, transcatheter valve implantation
may be a good temporary solution.
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